SmartCella Raises EUR 50 Million to Accelerate Growth and Commercialization
SmartCella Raises EUR 50 Million to Accelerate Growth and Commercialization
STOCKHOLM, July 8, 2024 /PRNewswire/ -- SmartCella Holding AB ("SmartCella") today announces a new share issue raising approximately EUR 50 million to accelerate growth and support commercialization of the Extroducer and the company's cell and mRNA operations. The share issue was supported by existing large institutional investors such as Fjärde AP-fonden, AMF Pension and SEB-Stiftelsen, as well as a new long-term strategic investor, AstraZeneca (committing to approximately half of the share issue) and the new larger institutional investors Handelsbanken Fonder and RoosGruppen AB, at a pre-money valuation of approximately EUR 500 million.
2024年7月8日，斯德哥爾摩/ PRNewswire——SmartCella Holding Ab（"SmartCella"）宣佈進行新發行股票，募集約5000萬歐元，以加速增長，支持 Extroducer 以及公司的電芯和mRNA 業務的商業化發展。原有的大型機構投資者，如第四AP基金，AMF Pension 和SEb-Stiftelsen 等，以及新的長期戰略投資者 AstraZeneca 一起支持了這次發行股票，新的大型機構投資者 Handelsbanken Fonder 和 RoosGruppen Ab，預估估值爲約5000萬歐元。
SmartCella is a global innovative biotechnology company with a vision to combine novel delivery platforms, such as the FDA-cleared Extroducer, with developing cutting-edge cell, and mRNA therapies. The team consists of global scientists, innovators and visionaries dedicated to shape the future of targeted medicine through innovation and solid clinical data with the ambition of making targeted medicine a reality for many.
SmartCella 是一家全球創新性的生物技術公司，致力於將新型輸送平台（如經FDA審批的 Extroducer）與現代的細胞和mRNA 療法結合起來。團隊由全球科學家，創新者和有遠見的人士組成，專注於通過創新和實在的臨床數據來塑造靶向醫學的未來，並有野心讓靶向醫學成爲現實。
The capital raise was supported by existing large institutional investors Fjärde AP-fonden, AMF Pension, and SEB-Stiftelsen, and also included new investors such as AstraZeneca, Handelsbanken Fonder and RoosGruppen AB. Christian Kinch and Thomas von Koch remain major shareholders (via SWIB Holding AB). The capital raise is part of the overall strategic development and future-proofing of SmartCella which includes continued investments in the organization and infrastructure as well as increased commercialization and marketing efforts.
資本籌集得到了已有的大型機構投資者的支持，如第四AP基金，AMF Pension 和SEb-Stiftelsen，還包括了新的投資者，如AstraZeneca，Handelsbanken Fonder 和 RoosGruppen Ab。克里斯蒂安•金奇（Christian Kinch）和托馬斯•馮•科赫（Thomas von Koch）通過SWIb Holding AB 仍然是主要股東。此次資本籌集是 SmartCella 的總體戰略發展和未來保障的一部分，這包括在組織和基礎設施方面持續投資，以及加大商業化和營銷力度。
Another strategic building block is the previously announced new members to the Board of Directors of SmartCella, with Regina Fritsche-Danielson (Senior Vice President and Global Head of Research and Early Development, Cardiovascular, Renal and Metabolic Diseases at AstraZeneca), Anna Martling (Professor of Surgery and Scientific Director Life Science at Karolinska Institutet) and Claude Dartiguelongue (previously executive roles with Lonza, Thermo Fisher Scientific and Becton Dickinson and Company).
另一個戰略性的基石是以前宣佈的 SmartCella 董事會新增成員，其中包括 Regina Fritsche-Danielson（阿斯利康心血管、腎臟和代謝疾病研究和早期開發全球負責人），Anna Martling（卡羅林斯卡醫學院外科教授和生命科學科學主任）以及 Claude Dartiguelongue（之前擔任龍沙、賽默飛世爾和貝克騰•迪金森等公司的高管職務）。
Christian Kinch, founder and Chairperson of SmartCella comments: "We are profoundly grateful for the robust support shown for SmartCella by both our current and new investors. We have a strong shareholder base, featuring highly professional investors alongside a science-focused industry and technology leader like AstraZeneca. The investor endorsement underscores their confidence in our business model, our team, and our potential to revolutionize the treatment of some of the most severe diseases worldwide. SmartCella represents a compelling investment opportunity with an integrated business model that blends science, sustainability and impact. SmartCella is truly about advancing a healthier future."
SmartCella 的創始人兼主席克里斯蒂安金奇（Christian Kinch）表示：“我們對我們現有和新的投資者所表現出的對 SmartCella 的大力支持深表感激。我們擁有強大的股東基礎，包括高度專業的投資者以及阿斯利康這樣的以科學爲中心的行業和技術領導者。投資者對我們商業模式、團隊和革命性地改變全球最嚴重疾病的潛力表達了信心。SmartCella 是一個具有綜合性的商業模式的有力投資機會，結合了科學、可持續性和影響力。SmartCella 真正推動着更健康的未來。”
Niklas Prager, CEO of SmartCella, says: "We operate in the most exciting and attractive areas of biotech. Cell and gene therapy are currently the hottest areas in biotech research and investments, yet SmartCella remains somewhat of a hidden gem. With the new proceeds, we will continue to build our organization and drive accelerated growth. We will have a specific focus on ramping up commercialization of the Extroducer, which I believe is one of the most groundbreaking innovations in targeted delivery solutions, carrying therapies directly into otherwise hard-to-reach tumors or organs. The Extroducer, combined with our world-class research and knowledge in cell and mRNA therapies, makes SmartCella unique. This capital raise is a landmark event for us - and our journey has only just begun."
SmartCella 的首席執行官尼古拉斯•普拉格（Niklas Prager）表示：“我們在生物技術的領域中擁有最令人激動和吸引人的領域。現在，電芯和基因療法是生物技術研究和投資的熱點，然而 SmartCella 仍然保持了一定的實力。隨着新的資金流入，我們將繼續建設我們的組織，並加快增長步伐。我們將專注於加速推廣 Extroducer，我相信 Extroducer 是靶向輸送解決方案中最具突破性的創新之一，可將療法直接輸送到難以到達的腫瘤或器官中。Extroducer 與我們在電芯和mRNA 療法方面的世界級研究和知識相結合，使 SmartCella 獨一無二。此次資本籌集對我們來說是一個里程碑事件，我們的旅程才剛剛開始。”
Regina Fritsche-Danielson, Board Member of SmartCella adds: "At AstraZeneca, we recognize the potential of cell and gene therapies to slow, stop and reverse disease progression in areas where significant unmet need still exists. I am delighted to join the SmartCella Board of Directors, building on our existing collaboration with SmartCella and sharing our knowledge and skills to drive innovation in this rapidly advancing field."
SmartCella 董事會成員 Regina Fritsche-Danielson 表示：“在阿斯利康，我們認識到細胞和基因療法在仍存在顯著需求的領域中減緩、停止和逆轉疾病進展的潛力。我很高興加入 SmartCella 董事會，與 SmartCella 建立更多聯繫，分享我們的知識和技能，推動這個快速發展領域的創新。”
Skandinaviska Enskilda Banken acted as financial advisor to SmartCella.
斯堪的納維亞恩斯基爾達銀行擔任 SmartCella 的財務顧問。
Contact
Niklas Prager, CEO, +46 76 811 77 44
Nina Nornholm, Head of Corporate Communication, +46 708 550 356
聯繫人
尼古拉斯•普拉格，首席執行官，+46 76 811 77 44
Nina Nornholm，公司傳播負責人，+46 708 550 356
About SmartCella Holding AB
關於 SmartCella Holding AB
SmartCella, founded in 2014, is a world-leading biotechnology company pioneering the future of targeted therapies by combining novel delivery platforms, such as the FDA-cleared Extroducer (an endovascular device that enables direct infusion to hard-to-reach organs and tumors), with cutting-edge cell and mRNA therapies. The team consists of global scientists, innovators and visionaries dedicated to shape the future of targeted medicine through innovation and solid clinical data with the ambition of making targeted medicine a reality for many.
SmartCella 成立於 2014年，是一家世界領先的生物技術公司，通過結合新型輸送平台（如經FDA認證的 Extroducer）與尖端的電芯和mRNA 療法，開創了靶向治療領域的未來。團隊由全球科學家、創新者和有遠見的人士組成，他們致力於通過創新和實在的臨床數據塑造靶向醫學的未來，並有野心讓靶向醫學成爲現實。SmartCella 經營兩個業務：靶向輸送和電芯/mRNA 療法。
SmartCella operates in two business segments: Targeted Delivery and Cell/mRNA Therapies.
關注 SmartCella 的發展：
Read more
閱讀更多
Follow SmartCella on LinkedIn
SmartCella 成立於 2014年，是一家世界領先的生物技術公司，通過結合新型輸送平台（如經FDA認證的 Extroducer）與尖端的電芯和mRNA 療法，開創了靶向治療領域的未來。團隊由全球科學家、創新者和有遠見的人士組成，他們致力於通過創新和實在的臨床數據塑造靶向醫學的未來，並有野心讓靶向醫學成爲現實。SmartCella 經營兩個業務：靶向輸送和電芯/mRNA 療法。LinkedIn
This information was brought to you by Cision
本信息由Cision提供
The following files are available for download:
以下文件可供下載：
|
Press release SmartCella capital raise 240708 | |
|
smartcella |
|
SmartCella 發佈資本籌集 240708 | |
|
smartcella |
譯文內容由第三人軟體翻譯。